Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates abeta, tau, immunity and lipid processing
"Dual GIP and GLP-1 receptor agonist tirzepatide alleviates hepatic steatosis and modulates gut microbiota and bile acid metabolism in diabetic mice" Int Immunoph PubMed Tirzepatide is a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors and is a promising therapeutic option for type 2 diabetes mellitus (T2DM)
The exact pathophysiology involves increased intraluminal pressure, weakening of the colonic wall, and alterations in gut microbiota, though the precise mechanisms remain under investigation
Tirzepatide can cause gastrointestinal changes that increase fluid loss
A PCAC recommendation is not a rule, and a category change would not constitute FDA approval or create blend-level efficacy data
Both involve subcutaneous needles, dosing schedules, and pharmacy conversations that sound remarkably similar